Johnson & Johnson (J&J) has secured marketing authorization from the US FDA for its Ottava robotic surgical system, allowing it to enter the soft-tissue robotic surgery market. The system, approved for several general surgery procedures, will initially launch with select US customers, challenging Intuitive Surgical's dominance.
Stocks were mixed Wednesday, with a tech split as chip stocks rallied and software lagged. An OpenAI security incident is seen as a catalyst for cybersecurity firms. Johnson & Johnson received early FDA approval for its Ottava robotic surgical system, and Goldman Sachs launched a new platform for wealthy clients to invest in private companies.
Taipei Veterans General Hospital is combining neoadjuvant chemotherapy with robotic surgery to treat head and neck cancers. This approach aims to reduce surgical trauma, preserve appearance and function, and improve treatment quality. A patient with recurrent tongue cancer successfully recovered after this treatment, avoiding traditional extensive surgery and subsequent radiation or chemotherapy.
